The emerging role of electronic medical records in pharmacogenomics

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 3, 2011, Pages 379-386

  Wilke, R A ^a   Xu, H ^a   Denny, J C ^a   Roden, D M ^a   Krauss, R M ^b   McCarty, C A ^c   Davis, R L ^d   Skaar, T ^e   Lamba, J ^f   Savova, G ^g,h,i  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^c MARSHFIELD CLINIC   (United States)

^d KAISER PERMANENTE   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g MAYO CLINIC   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; DRUG EFFICACY; ELECTRONIC MEDICAL RECORD; FUNCTIONAL GENOMICS; GENETIC ASSOCIATION; GENOTYPE; HEALTH CARE; INFORMATION TECHNOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

DECISION SUPPORT TECHNIQUES; ELECTRONIC HEALTH RECORDS; GENETIC ASSOCIATION STUDIES; GENOMICS; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; RESEARCH DESIGN;

EID: 79951811383     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.260     Document Type: Review

References (50)

1. Ashley, E.A. et al. Clinical assessment incorporating a personal genome. Lancet 375, 1525-1535 (2010).
2. Lifton, R.P. Individual genomes on the horizon. N. Engl. J. Med. 362, 1235-1236 (2010).
3. DesRoches, C.M. et al. Electronic health records in ambulatory care - a national survey of physicians. N. Engl. J. Med. 359, 50-60 (2008).
4. Jha, A.K. et al. Use of electronic health records in U.S. hospitals. N. Engl. J. Med. 360, 1628-1638 (2009).
5. Shea, S. & Hripcsak, G. Accelerating the use of electronic health records in physician practices. N. Engl. J. Med. 362, 192-195 (2010).
6. Pakhomov, S., Bjornsen, S., Hanson, P. & Smith, S. Quality performance measurement using the text of electronic medical records. Med. Decis. Making 28, 462-470 (2008).
7. Denny, J.C., Miller, R.A., Waitman, L.R., Arrieta, M.A. & Peterson, J.F. Identifying QT prolongation from ECG impressions using a general-purpose Natural Language Processor. Int. J. Med. Inform. 78 (suppl. 1), S34-S42 (2009).
8. Chan, K.A. et al. The HMO Research Network. In Pharmacoepidemiology 4th edn., (ed. Strom, B.L.) 261-270 (Wiley & Sons, West Sussex, UK, 2007).
9. Xu, H., Stenner, S.P., Doan, S., Johnson, K.B., Waitman, L.R. & Denny, J.C. MedEx: a medication information extraction system for clinical narratives. J. Am. Med. Inform. Assoc. 17, 19-24 (2010).
10. McCarty, C.A. & Wilke, R.A. Biobanking and pharmacogenomics. Pharmacogenomics 11, 637-641 (2010).
11. Barber, M.J. et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS ONE 5, e9763 (2010).
12. McCarty, C.A. et al. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. Personalized Med 2, 49-79 (2005).
13. Roden, D.M. et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84, 362-369 (2008).
14. Ormond, K.E., Cirino, A.L., Helenowski, I.B., Chisholm, R.L. & Wolf, W.A. Assessing the understanding of biobank participants. Am. J. Med. Genet. A 149A, 188-198 (2009).
15. Ritchie, M.D. et al. Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. Am. J. Hum. Genet. 86, 560-572 (2010).
16. McDonald, C.J. Protocol-based computer reminders, the quality of care and the non-perfectability of man. N. Engl. J. Med. 295, 1351-1355 (1976).
17. McDonald, C.J., Murray, R., Jeris, D., Bhargava, B., Seeger, J. & Blevins, L. A computer-based record and clinical monitoring system for ambulatory care. Am. J. Public Health 67, 240-245 (1977).
18. Meystre, S.M., Savova, G.K., Kipper-Schuler, K.C. & Hurdle, J.F. Extracting information from textual documents in the electronic health record: a review of recent research. Yearb. Med. Inform. 128-144 (2008).
19. Evans, W.E., Relling, M.V., Rodman, J.H., Crom, W.R., Boyett, J.M. & Pui, C.H. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med. 338, 499-505 (1998).
20. Wilke, R.A., Moore, J.H. & Burmester, J.K. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet. Genomics 15, 415-421 (2005).
21. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
22. Wilke, R.A. et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6, 904-916 (2007).
23. Klein, T.E. et al.; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
24. Friedman, C. A broad-coverage natural language processing system. Proc. AMIA Symp. 270-274 (2000).
25. Chhieng, D., Day, T., Gordon, G. & Hicks, J. Use of natural language programming to extract medication from unstructured electronic medical records. AMIA Annu. Symp. Proc. 908 (2007).
26. Jagannathan, V. et al. Assessment of commercial NLP engines for medication information extraction from dictated clinical notes. Int. J. Med. Inform. 78, 284-291 (2009).
27. Wilke, R.A., Berg, R.L., Linneman, J.G., Zhao, C., McCarty, C.A. & Krauss, R.M. Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository. Basic Clin. Pharmacol. Toxicol. 103, 354-359 (2008).
28. Vandenbroucke, J.P. & Psaty, B.M. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 300, 2417-2419 (2008).
29. McClure, D.L., Valuck, R.J., Glanz, M., Murphy, J.R. & Hokanson, J.E. Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. J. Clin. Epidemiol. 60, 812-818 (2007).
30. Mareedu, R.K. et al. Use of an electronic medical record to characterize cases of intermediate statin-induced muscle toxicity. Prev. Cardiol. 12, 88-94 (2009).
31. Wilke, R.A., Reif, D.M. & Moore, J.H. Combinatorial pharmacogenetics. Nat. Rev. Drug Discov. 4, 911-918 (2005).
32. Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R. & Lin, J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30, 1280-1287 (2002).
33. Riedmaier, S. et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin. Pharmacol. Ther. 87, 65-73 (2010).
34. Link, E. et al.; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
35. Keskitalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, P.J. & Niemi, M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86, 197-203 (2009).
36. Onitilo, A.A. et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res. Treat. 115, 643-650 (2009).
37. Lash, T.L. et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 49, 305-312 (2010).
38. Dezentjé, V.O. et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J. Clin. Oncol. 28, 2423-2429 (2010).
39. Kelly, C.M. et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340, c693 (2010).
40. A ubert, R.E. et al. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 27, 9s abstr CRA508 (2009).
41. Liao, K.P. et al. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care Res. (Hoboken). 62, 1120-1127 (2010).
42. McAlpine, D.E., O'Kane, D.J., Black, J.L. & Mrazek, D.A. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin. Proc. 82, 1065-1068 (2007).
43. Kivistö, K.T. et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14, 523-525 (2004).
44. Krauss, R.M. et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117, 1537-1544 (2008).
45. Loukides, G., Gkoulalas-Divanis, A. & Malin, B. Anonymization of electronic medical records for validating genome-wide association studies. Proc. Natl. Acad. Sci. USA 107, 7898-7903 (2010).
46. Mitchell, D.R. & Mitchell, J.A. Status of clinical gene sequencing data reporting and associated risks for information loss. J. Biomed. Inform. 40, 47-54 (2007).
47. Fargher, E.A. et al. Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics 8, 1511-1519 (2007).
48. Gardner, D. Using genomics to help predict drug interactions. J. Biomed. Inform. 37, 139-146 (2004).
49. Bassi, J., Lau, F. & Bardal, S. Use of information technology in medication reconciliation: a scoping review. Ann. Pharmacother. 44, 885-897 (2010).
50. Brownstein, J.S., Sordo, M., Kohane, I.S. & Mandl, K.D. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS ONE 2, e840 (2007).